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ABSTRACT
Pulmonary function (PF) was studied in 69 consecutive patients with hematologic diseases, with a minimum 5-year
(range, 5-13 years) follow-up after allogeneic stem cell transplantation from an HLA-matched sibling. Fifty-six
patients (81%) received total body irradiation based myeloablative stem cell transplantation (MT) and 13 (19%)
underwent nonmyeloablative stem cell transplantation (NST). Thirty-one patients (45%) developed a late decrease
in PF from baseline, 25 with a restrictive and 6 with an obstructive pattern PF abnormality. Twelve patients (17%)
were symptomatic, 8 with a severe restrictive PF defect, but none required supplemental oxygen. The incidence of
developing a late PF abnormality was comparable in MT (24 of 56) and NST (5 of 13; P  .51). In multivariate
analysis, chronic graft-versus-host disease (relative risk, 16) and pretransplantation diffusion capacity for carbon
monoxide or forced expiratory volume in the first second<80%predicted were independently associated with a late
decrease in PF from baseline (relative risk, 7). Our results indicate that late PF abnormality is common after MT
and NST. Patients with a low pretransplantation diffusion capacity for carbon monoxide of or forced expiratory
volume in the first second who developed chronic graft-versus-host disease were most severely affected. Longer
follow-up is needed to determine whether PF will continue to decrease or reach a plateau and whether more
patients with PF abnormality will eventually become symptomatic.
© 2006 American Society for Blood and Marrow Transplantation
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(NTRODUCTION
Despite the success in treating otherwise fatal
isease, allogeneic stem cell transplantation (SCT)
s associated with multiple and life-threatening
omplications from organ damage. Lung injury is a
requent complication after allogeneic SCT [1-7].
n our experience in adults with hematologic ma-
ignancies receiving SC transplants from HLA-
dentical siblings, noninfectious pulmonary deaths
ccounted for 66% of transplant-related mortality
ccurring mainly in the ﬁrst 6 months after SCT
8]. Delayed pulmonary injury can also occur: the aifetime risk of chronic pulmonary dysfunction in
ong-term SCT survivors ranges from 30% to 60%
1,9-11], depending on donor source and elapsed
ime from SCT. Chronic pulmonary dysfunction in
ong-term SCT survivors can be of an obstructive or
estrictive pattern [1,7,9,12-14]. In addition, an as-
ociation of defective pretransplantation pulmonary
unction (PF) and the development of obstructive
F abnormality after transplantation have been re-
ently reported [15]. Pulmonary dysfunction has
een linked to chronic graft-versus-host disease
cGVHD) in children undergoing SCT [7] and in
dults with unrelated SC transplants [16]. Reduced
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B. N. Savani et al.1262ntensity SCT has become increasingly popular
ased on the assumption that lower intensity con-
itioning regimens will cause less direct organ dam-
ge, resulting in an improvement in long-term out-
omes. Better identiﬁcation of pretransplantation
actors associated with worsening PF are needed to
eﬁne patients at greatest risk who might beneﬁt
rom preventive strategies. We describe PF abnor-
alities in a cohort of patients surviving 5 years
fter myeloablative SCT (MT) and nonmyeloabla-
ive SCT (NST) and identify pre- and post-trans-
lantation risk factors.
ETHODS
tudy Group
Sixty-nine consecutive patients who underwent
ransplantation between September 1993 and March
001 (minimum 5-year follow-up after SCT) were
ncluded in this analysis. All received SCT from an
LA-identical sibling in 5 successive National, Heart,
ung and Blood Institute (NHLBI) institutional review
oard-approved protocols (93-H-0212, 97-H-0099, 97-
-0202, 99-H-0046, and 99-H-0050). All patients and
onors gave written informed consent according to prin-
iples outlined in the Declaration of Helsinki.
ransplantation Regimens
Conditioning regimens. Two approaches were eval-
ated. For MT (n  56), total body irradiation (TBI)
t 1360 rad in 8 fractions in 4 days was followed by
yclophosphamide 60 mg/kg  2 days and bone mar-
ow transplantation (n  18) or granulocyte colony-
timulating factor (G-CSF)-mobilized peripheral
lood stem cell transplantation (PBSCT; n  38). In
ebilitated or older patients, NST (n  13) consisted
f cyclophosphamide 120 mg/kg plus ﬂudarabine 125
g/m2 and G-CSF-mobilized PBSCT (patients with
plastic anemia or at increased risk for graft rejection,
e, those with heavy transfusion burden or evidence of
lloimmunization, also received antithymocyte
lobulin 40 mg/kg intravenously on days 5, 4,
3, and 2).
GVHD prophylaxis. Patients undergoing MT re-
eived cyclosporine alone days 4 to 120-180. All
atients undergoing NST received cyclosporine with
ethotrexate 5 mg/m2 on days 1, 3, and 6 or
ycophenolate mofetil 1 g orally 2 times daily.
Transplantation. Patients undergoing NST re-
eived an unmanipulated T cell-replete PBSCT. T
ell depletion was performed in all MTs. In the ﬁrst
rotocol (93-H-0212), stem cells were collected after
one marrow harvesting and were depleted of T cells
y elutriation [17]. In all subsequent protocols, the
onor underwent G-CSF-mobilized peripheral blood
pheresis followed by stem cell selection. In protocol d7-H-0099, T cells were depleted by CD34 selection
n the “Ceprate SC” immunoabsorption column, fol-
owed by negative selection of T cells using anti-CD2
CellPro, Bothell, Wash). More recent protocols used
he Isolex 300i immunomagnetic cell separation sys-
em (version 2.5, Nexell Therapeutics, Irvine, Calif)
or positive selection of CD34 cells, followed by
egative selection of T cells using an antibody cocktail
f anti-CD2, anti-CD6, and anti-CD7, as previously
escribed [18].
Donor lymphocyte infusion. In MT in the absence of
VHD or complete molecular remission of chronic
yeloid leukemia (CML), T cells were added back
etween days 30 and 100. Patients undergoing NST
eceived donor lymphocyte infusion for disease pro-
ression or for persistent mixed T cell chimerism after
yclosporine tapering.
Supportive care. Standard prophylaxis against infec-
ion included ﬂuconazole to day 100, Bactrim for 6
onths after transplantation, and weekly surveillance
or cytomegalovirus antigenemia, as described previ-
usly [18,19]. Acute GVHD (aGVHD) was managed
ith high-dose steroids. Steroid-refractory patients
eceived treatment with daclizumab (anti-CD25
onoclonal antibody) alone or in combination with
nﬂiximab (anti-tumor necrosis factor), as described
reviously [20].
ulmonary Function Tests
Baseline PF was obtained in all patients 5 to 21
ays before SCT, after SCT at 3 months, 6 months,
nd 1 year, and thereafter annually when possible. In
atients with a concurrent acute respiratory illness, PF
ests were deferred until recovery from illness or re-
urn to baseline status. Ventilatory capacity was mea-
ured by forced vital capacity, forced expiratory vol-
me in the ﬁrst second (FEV1), ratio of FEV1 to
orced vital capacity, and peak expiratory ﬂow. Lung
olume measurements included vital capacity, total
ung capacity (TLC), residual volume, and ratio of
esidual volume to TLC. Diffusion capacity for car-
on monoxide (DLCO) was determined by using a
arbon monoxide single-breath technique with cor-
ection for hemoglobin concentration. PF was ex-
ressed as a percentage of the predicted value in
ealthy controls with corresponding age, sex, and
moking habits. Eligibility criteria for enrollment into
rotocols included a DLCO 60% of predicted.
efinitions
Stringent criteria for the deﬁnition of abnormal
F results were chosen because of inherent variability
n the tests employed. Abnormal PF before transplan-
ation was deﬁned as DLCO and/or FEV1 80%
redicted. PF abnormality after transplantation was
eﬁned as restrictive when there was signiﬁcant de-
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Late Pulmonary Complication after Stem Cell Transplantation 1263line from baseline in DLCO and TLC and obstruc-
ive pattern with decline in FEV1 and ratio of FEV1 to
orced vital capacity. We deﬁned a mild to moderate
F abnormality after transplantation as a 5%-15 %
ecline in DLCO, FEV1, or TLC and severe as a
15% decline compared with values before transplan-
ation. Symptomatic PF abnormality was deﬁned as
ecline in PF from baseline (as deﬁned above), with
ny combination of 2 respiratory symptoms: short-
ess of breath, wheezing, fatigue, and cough unrelated
o acute illness lasting 4 weeks. Smokers were de-
ned as patients who regularly smoked 1 pack of
igarettes within 12 months before PBSCT for a min-
mum of 2 years.
tatistical Methods
Summary statistics, such as proportions, means,
tandard deviations, 95% conﬁdence intervals, medi-
ns, and ranges, were used to describe patient charac-
eristics, pretransplantation variables, and post-trans-
lantation outcomes. Kaplan-Meier curves were used
o display distributions of survival and events among
ubgroups of patients, and Cox proportional hazard
odels with univariate or multivariate covariates were
sed to evaluate the effects of covariates, such as
moking, pretransplantation abnormal PF, type of
ransplantation, CD34 cell dose, and aGVHD/
GVHD on survival times. Variables entered into the
ultivariate models were age, smoking, abnormal PF
efore transplantation, aGVHD, and cGVHD. Statis-
ical associations between pretransplantation variables
ere investigated by using correlation analysis, includ-
ng Pearson correlation coefﬁcients and Spearman
ank correlation coefﬁcients, and multiple regression
nalysis. Statistical tests based on t tests, chi-square
ests, and F tests were used to evaluate the statistical
igniﬁcance of covariates in multiple regression mod-
ls or Cox proportional hazard models. Data analysis
as performed with SPSS 14 for Windows (SPSS Inc,
hicago, Ill).
ESULTS
atients
A total of 199 patients with hematologic disorders
malignant in 191; benign in 8) underwent allogeneic
CT between September 1993 and March 2001 ac-
ording to NHLBI protocols. Of these, 83 patients
urvived beyond 5 years and 69 patients were available
or PF and clinical assessments 5 years after transplan-
ation. In this cohort of 69 patients, all survived at the
ime of analysis. Patient characteristics of the 69 pa-
ients included in this analysis are summarized in Ta-
le 1. Median follow-up of the study population was
.5 years (range, 5-13 years). The median age of pa-
ients at transplantation was 37 years (range, 10-68 bears). The median ages of patients undergoing MT
nd NST were 37 years (range, 10-55 years) and 34
ears (range, 15-68 years), respectively. Sixty-ﬁve pa-
ients (94%) had hematologic malignancies and 4 had
enign hematologic disorders (severe aplastic anemia
n 2; paroxysmal nocturnal hemoglobinuria in 2). Be-
ore transplantation 11 patients (16%) were smokers.
retransplantation PF abnormalities (DLCO and/or
EV1 80% predicted) were observed in 19 patients
27.5%). There was no difference between patients
ith normal and abnormal PF results. Fifty-six pa-
ients (81%) underwent MT and 13 (19%) underwent
ST. The median CD34 cell dose infused was
.26  106/kg (range, 0.98-21.1  106/kg).
raft-versus-Host Disease
Among long-term survivors, 25 patients (36.2%)
ad a history of aGVHD (grade II-IV) and 43 patients
62.3%) had cGVHD (limited in 39; extensive in 4) at
ome point after transplantation. Of 17 patients with
bnormal PF before transplantation, 14 developed
imited and 3 extensive cGVHD. Of 26 patients who
ad normal PF before transplantation, 25 developed
imited and 1 patient developed extensive cGVHD.
At the time of this analysis, only 3 patients
4.3%) remained on immunosuppressive therapy for
GVHD. Incidences of cGVHD were 58% after
T and 76% after NST. Of 19 patients with ab-
ormal PF before transplantation (DLCO and/or
EV1 80% predicted), 17 developed cGVHD ver-
us 26 of 50 with normal PF before transplantation
eveloping cGVHD (P  .0049).
F Abnormality
Details of PF abnormality are summarized in
able 2. Thirty-one patients (45%) had a decline in
F during long-term follow-up, 25 (36%) with a
estrictive pattern and 6 (9%) with an obstructive
attern. In 22 patients the abnormalities were mild
o moderate in severity (5%-15% decline in pre-
icted values) and severe (15%) in 9 patients.
welve of these 31 patients (17% of all 69 patients)
ere symptomatic (Table 3), 8 with a severe restric-
ive and 4 with an obstructive pattern of PF abnor-
ality after transplantation. None required supple-
ental oxygen. All but 1 had a history of cGVHD.
edian time to PF decline from baseline after
ransplantation was 37 months (range, 6-85 months;
igure 1a) and median time to symptomatic PF
bnormality was 49 months (range, 12-85 months).
retransplantation Factors Affecting Late PF
Table 4 lists PF changes over 7 years after SCT in
atients with abnormal PF before transplantation with
80% predicted value in DLCO and/or FEV1 at
aseline. The nature of the pretransplantation abnor-
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B. N. Savani et al.1264ality (obstructive or restrictive pattern) did not in-
uence the evolution toward a global deterioration in
LCO, FEV1, and TLC irrespective of whether the
nitial abnormality was only in DLCO or FEV1 (Table
). We therefore deﬁned abnormal PF before trans-
lantation as 80% predicted value in DLCO and/or
EV1. In univariate analysis the pretransplantation
ariables, smoking and abnormal PF before transplan-
able 1. Patient Characteristics and Univariate Analysis
Factor
Patients,
n (%)
retransplantation variables
Age (median, 37 y)
<37 34
>37 35
Gender
Female 30 (43)
Male 39 (57)
Race
Asian 11 (16)
Black 5 (7)
Hispanic 24 (35)
White 29 (42)
Smoking
No 58 (84)
Yes 11 (16)
Abnormal PF
No 50 (72)
Yes 19 (28)
ransplant-related variables
Type of transplant
MST 56 (81)
NST 13 (19)
CD34 dose (median, 5.26 million cells/kg)
<5.26 34
>5.26 35
Acute GVHD
No 44 (64)
Yes 25 (36)
Chronic GVHD
No 26 (38)
Yes 43 (62)
F indicates pulmonary function; MT, myeloablative stem cell tra
graft-versus-host disease.
able 2. Details of Post-transplantation PF Abnormality (versus
aseline Value)
Patients with Decline in PF (n  31) Patients, n
ymptomatic 12
ype of PF abnormality
Restrictive 25
Obstructive 6
everity of PF abnormality
Mild to moderate (5%-15% decline)* 22
Severe (>15% decline)* 9
F indicates pulmonary function.
Decrease in diffusion capacity for carbon monoxide and/or forced
expiratory volume in the ﬁrst second and/or total lung capacity
Cfrom baseline.ation, were associated with a signiﬁcant decline in PF
rom baseline (Table 1, Figure 1b). Age, gender, and
ace did not signiﬁcantly affect the risk of late PF
bnormality (Table 1). Ten of 11 smokers developed
ate decline in PF from baseline compared with only
1 of 58 nonsmokers (P  .001). Male sex was signif-
cantly associated with symptomatic PF abnormality
10 of 11 smokers were men). In multivariate analysis
Table 5), among pretransplantation factors, abnormal
F before transplantation was predictive for asymp-
omatic and symptomatic late declines in PF from
aseline (relative risk, 7; P  .02 for both).
ransplant-related Factors Affecting
ate PF Abnormality
The incidence of late PF abnormality was compa-
able in MT (26 of 56) and NST (5 of 13; P  .51;
able 1). In univariate analysis, cGVHD was signiﬁ-
antly associated with a higher incidence of late PF
bnormality (Figure 1c) and aGVHD was signiﬁcantly
ssociated with symptomatic PF abnormality. Neither
bnormality,
n (%) P
Symptomatic PF
Abnormality, n
(%) P
.195 .13
3 (38.2) 2 (5.8)
8 (51.4) 10 (28.5)
.495 .038
4 (46.6) 2 (6.6)
7 (43.5) 10 (25.6)
.772 .885
6 (54.5) 2 (18.1)
3 (60) 1 (20)
0 (41.6) 3 (12.5)
2 (41.3) 6 (20.6)
.001 <.0001
1 (36.2) 2 (3.4)
0 (90.9) 10 (90.9)
<.0001 .002
5 (30) 4 (8)
6 (84.2) 8 (42.1)
.419 .402
6 (46.4) 9 (16)
5 (38.4) 3 (23)
.195 .397
3 (38.2) 5 (14.7)
8 (51.4) 7 (20)
.127 .02
7 (38.6) 4 (9)
4 (56) 8 (32)
<.0001 .019
2 (7.6) 1 (3.8)
9 (67.4) 11 (25.5)
ation; NST, nonmyeloablative stem cell transplantation; GVHD,PF A
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Late Pulmonary Complication after Stem Cell Transplantation 1265igure 1d, Table 1) inﬂuenced asymptomatic or symp-
omatic late PF abnormality. In multivariate analysis
Table 5), only cGVHDwas found to be predictive for
symptomatic (relative risk, 16; P  .001) and symp-
omatic (relative risk, 18; P  .002) late declines in PF
rom baseline.
erial Measurements of PF in Different
isk Categories
Table 6 presents the results of serial PF measure-
ents for the variables identiﬁed as signiﬁcant in mul-
ivariate analysis. Twenty-four patients with no ab-
ormal PF before transplantation and who did not
evelop cGVHD maintained the same level of func-
ion over the observation period, with no emergence
f restrictive or obstructive defects. In contrast, 26
atients with no abnormality in PF before transplan-
ation who developed cGVHD showed a marked pro-
ressive decline in DLCO and TLC but no decrease
n FEV1, indicating that cGVHD caused predomi-
antly restrictive pulmonary damage. It was notable
hat the PF abnormalities continued despite no clini-
al evidence of active cGVHD; only 2 of 32 patients
ith late PF decline were receiving immunosuppres-
ive therapy 5 years after SCT. It was not possible to
easure the exact time to PF decline after develop-
ent of cGVHD because of the infrequent timing of
F measurements. Most profoundly affected was the
roup of 17 patients with abnormal PF before trans-
lantation who developed cGVHD. Only 2 patients
ith abnormal PF before transplantation did not de-
elop cGVHD (PF data not shown), suggesting that
bnormal PF might predispose to cGVHD.
ISCUSSION
This study emphasizes the importance of long-
erm follow up of SC transplant recipients to iden-
ify delayed defects in PF and to determine caus-
tive factors for pulmonary damage. It is disturbing
o observe that delayed lung injury is a signiﬁcant
roblem after SCT; in our cohort of 69 patients
-13 years after SCT, 17% were symptomatic due
o pulmonary insufﬁciency and 45% had PF dete-
ioration. Further, pulmonary damage appeared to
e a slowly progressive process. Continued fol-
ow-up of SC transplant recipients 1 and 2 decades
rom SCT will be required to fully characterize the
atural history of this problem.
Only patients who had no abnormal PF before
ransplantation and did not develop cGVHD ap-
eared to be spared from progressive deterioration in
F. Studies have shown that poor PF before trans-
lantation is associated with higher transplant-related
ortality and morbidity [15,21]. Somewhat predict-ably, pulmonary defects acquired before transplanta-Ta N 1 2 3 4 5 6 7 8 9 10 11 12 PF *1 †O
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B. N. Savani et al.1266ion were an important factor for increasing the risk of
ost-transplantation pulmonary defects. It is impor-
ant to note that the cohort of patients who underwent
ransplantation with a DLCO 80% predicted had
urther deterioration in all PF parameters and 4 of 11
atients developed symptomatic PF abnormalities.
imilarly, patients with an FEV1 80% predicted
efore transplantation had deterioration in all PF pa-
ameters and 5 of 8 patients developed symptomatic
igure 1. Time to a signiﬁcant decline in pulmonary function (from
apacity for carbon monoxide and/or forced expiratory volume in th
ransplantation, (c) present versus absent chronic graft-versus-host
NST) stem cell transplantation.
able 4. Serial PF Measurements in Patients with Abnormal PF befor
PF before Transplantation Before SCT 1 y
LCO <80% predicted (n  11) 11 10
DLCO 73  2.0 77 
FEV1 88  4.8 85 
TLC 86  2.5 83 
EV1 <80% predicted (n  8) 8 8
DLCO 90  8.9 74 
FEV1 73  1.7 76 
TLC 87  2.2 83 
F indicates pulmonary function; SCT, stem cell transplantation; D
volume in the second; TLC, total lung capacity.Mean  SEM.F abnormalities. Thus, in selecting patients for SCT
ith diminished lung function, the possibility of fur-
her deterioration should be considered.
We next sought to identify transplant-related fac-
ors that might predict delayed PF defects. Radiation
amage to the lung during TBI has been described in
nimal models [22,23] and there is an extensive liter-
ture linking restrictive PF defects with TBI [1,24-
6]. Factors that affect radiation lung damage are the
ine) in (a) all patients, (b) abnormal pulmonary function (diffusion
second 80% predicted) versus normal pulmonary function before
(cGVHD), and (d) myeloablative (MT) versus nonmyeloablative
plantation*
3 y 5 y 6 y 7 y
8 10 6 5
70  3.5 66  3.2 60  3.3 61  5.3
85  5.0 83  5.2 69  7.7 69  10.6
84  4.9 80  5.9 71  6.7 71  9.2
6 7 3 4
76  6.1 68  10.4 61  1.3 59  0.3
74  3.4 69  3.2 65  13.7 57  4.1
83  3.5 78  7.1 70  12.9 70  8.2
, diffusion capacity for carbon monoxide; FEV1, forced expiratorybasel
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Late Pulmonary Complication after Stem Cell Transplantation 1267otal dose, the dose fractionation employed, and the
cute dose rate per fraction. The TBI schedule used in
ur patients followed a standard approach in which
2-13.6 cGy is administered in 8 fractions of 150-170
Gy over 4 days. More recently, lung shielding was
ntroduced to reduce the total lung dose to 6 cGy. In
previous study, we identiﬁed pulmonary failure as
he most common cause of nonrelapse mortality after
CT but did not ﬁnd any signiﬁcant improvement in
utcome in patients receiving lower lung doses [8]. In
his analysis we had the opportunity to compare out-
omes of patients receiving TBI with a smaller cohort
f patients receiving a reduced intensity regimen of
udarabine and cyclophosphamide. Surprisingly,
here was no difference in the incidence of late PF
bnormalities between the TBI and non-TBI groups
46.4% versus 38.4%, respectively; P  .419). How-
ver, the lack of difference between the 2 cohorts
annot reliably be ascribed to the absence of an ad-
able 5. Multivariate Analysis: Factors Affecting Late Decline in PF
rom Baseline
Factor
Relative
Risk 95% CI P
F abnormality
Abnormal PF before transplantation
No 1
Yes 7 1.3-42 .02
Chronic GVHD
No 1
Yes 16 2.9-68 .001
ymptomatic PF abnormality
Abnormal PF before transplantation
No 1
Yes 7 1.3-39 .02
Chronic GVHD
No 1
Yes 18 3.0-114 .002
F indicates pulmonary function; CI, conﬁdence interval; GVHD,
graft-versus-host disease.
able 6. Pretransplantation PF and cGVHD: Serial PF Measurement
Before SCT
ormal PF† and no cGVHD (n  24) 24
DLCO 94  2.5 91
FEV1 103  2.0 103
TLC 94  2.0 97
ormal PF† and cGVHD (n  26) 26
DLCO 102  3.4 91
FEV1 99  2.2 101
TLC 96  2.3 99
bnormal PF† and cGVHD (n  17) 17
DLCO 84  4.6 76
FEV1 85  3.4 83
TLC 85  1.9 84
F indicates pulmonary function; SCT, stem cell transplantation; c
carbon monoxide; FEV1, forced expiratory volume in the secon
Mean  SEM, percentage predicted value.
PF before transplantation; data for 2 patients with abnormal PF before terse effect of TBI, because the nonirradiated reduced
ntensity conditioning recipients represent an older
atient population with different pretransplantation
reatments.
Obstructive and restrictive forms of PF abnormal-
ties have been reported in long-term survivors of
llogeneic SCT, with incidences of 20%-50%
7,9,12,26]. Collagen deposition and development of
brosis in the interstitial (in restrictive pattern) or
eribronchial (in obstructive pattern) space are be-
ieved to contribute to the characteristic PF abnormal-
ty. An obstructive pattern PF is classically linked to
GVHD [27,28], but we found more patients devel-
ping a predominantly restrictive pattern of PF ab-
ormality.
In multivariate analysis, cGVHD was the only
ransplant-related factor that emerged as a variable
igniﬁcantly affecting PF. Chronic GVHD was more
ommon in the non-TBI recipients (76% versus
8%). The effect of cGVHD on development of PF
efects was striking, with a 16- to 18-fold increase in
elative risk of PF abnormalities for any degree of
GVHD.
Clinical and experimental data suggest that the
rogression to a chronic proﬁbrotic pulmonary toxic-
ty involves the secretion of cytokines and chemokines
23,29]. Several studies have shown an association be-
ween GVHD and pulmonary injury [2,6,27,28,30]. In
murine model, tumor necrosis factor  has been
hown to be with involved chronic lung injury [31].
lthough GVHD has been linked to pulmonary com-
lications after SCT, the pathogenesis and epidemi-
logy of chronic lung injury from cGVHD remains ill
eﬁned. In our study it sufﬁced to have a history of
ny degree of severity of cGVHD to increase the
robability of a delayed PF defect, suggesting that
GVHD sets up a process of long-term damage or
hat a subclinical form of isolated pulmonary cGVHD
3 y 5 y 6 y 7 y
23 22 7 9
95  3.1 94  2.1 91  4.1 89  3.2
103  3.0 103  2.8 107  7.0 109  4.3
96  3.1 97  2.4 99  6.0 97  4.3
21 25 10 5
89  3.7 81  3.5 81  4.2 80  6.3
97  3.6 95  4.1 94  4.9 98  4.4
93  3.5 95  3.3 83  4.2 82  3.8
12 16 6 7
75  3.8 68  4.8 60  3.3 61  3.7
83  4.6 79  4.1 69  7.7 67  7.3
83  3.9 80  4.3 71  6.7 74  6.7
; chronic graft-versus-host disease; DLCO, diffusion capacity for
, total lung capacity.s*
1 y
23
 3.6
 3.0
 3.0
21
 3.1
 3.3
 3.5
14
 3.8
 4.4
 3.5
GVHD
d; TLCransplantation and no cGVHD are not listed.
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B. N. Savani et al.1268ersists for many years. Measures to prevent late pul-
onary damage without preventing the protective ef-
ect of cGVHD on leukemic relapse are warranted.
he most severely affected subset of patients consisted
f those with pretransplantation pulmonary damage
nd cGVHD. The association of pretransplantation
F defects with cGVHD (17 of 19 patients) was strik-
ng and strongly suggests that pre-existing lung injury
s a provocative factor for cGVHD. However, the
rolonged intervals between PF measurements pre-
ented analysis of the relation between onset of
GVHD and decline in PF.
In conclusion, our results emphasize the impor-
ance of cGVHD as a key factor in progressive pul-
onary damage after all forms of allogeneic SCT.
owever, it should be noted that other factors not
ecognized in this analysis could have contributed to
he changes in PF observed. Further, these data are
etrospective and our ﬁndings need to be further val-
dated in prospective and larger studies.
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